Olanzapine Plus Carbamazepine in the Treatment of Bipolar I Mania
Olanzapine Plus Carbamazepine Versus Carbamazepine Alone in the Treatment of Manic or Mixed Episodes Associated With Bipolar I Disorder
Sponsor: Eli Lilly and Company
Listed as NCT00190892, this PHASE4 trial focuses on Bipolar Disorder and remains completed. Sponsored by Eli Lilly and Company, it has been updated 7 times since 2004, reflecting limited change activity. Mental health research at this phase helps define safety and dosing parameters for future study.
Status Flow
Change History
7 versions recorded-
Jan 2026 — Present [monthly]
Completed PHASE4
-
Sep 2025 — Present [monthly]
Completed PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE4
▶ Show 2 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE4
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE4
First recorded
Sep 2004
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Eli Lilly and Company
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Budapest, Hungary , Corfu, Greece , Debrecen, Hungary , Epping, Australia , Everton Park, Australia , Frankston, Australia , Gyula, Hungary , Kavala, Greece , Malvern, Australia , Moscow, Russia and 3 more locations